IMW 2019: Amrita Krishnan, MD on the Best Myeloma Maintenance Approach After Transplant

What is the best approach for maintenance therapy? How long should patients be on maintenance? Can I stop treatment if I'm minimal residual disease (MRD) negative? These important questions need to be answered if maintenance therapy is going to be applied properly for myeloma patients. Amrita Krishnan, MD, Director of the City of Hope multiple myeloma program is leading one of the largest studies in the nation to find answers to these questions. 

Learn More About This Maintenance Study

This trial can be joined before or after a stem cell transplant and is open at 98 centers across the United States as part of the largest transplant network in the country. 

Patients will be divided into two groups for maintenance therapy following a stem cell transplant 1) lenalidomide maintenance or 2) lenalidomide plus subq daratumumab maintenance. After two years of maintenance MRD testing will be performed. MRD-positive patients will continue on maintenance. MRD negative patients will be further randomized to a treatment group vs. non-treatment group. 

To learn more about this study, watch Dr. Krishnan describe the SWOG 1803 study at the recent IMW conference in Boston.